Obesity

Biotech Elaine Chen

STAT Plus: Novo Nordisk defends Ozempic’s price in face of Senate scrutiny

Biotech Elaine Chen

STAT Plus: Eli Lilly raises earnings guidance as it ramps up Mounjaro, Zepbound manufacturing

The Readout Elaine Chen

STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic

Health Elizabeth Cooney

Decline in heart failure deaths has been undone, led by people under 45

The Readout Elaine Chen

STAT Plus: A spending frenzy on obesity drugs

Biotech Elaine Chen

STAT Plus: New studies suggest GLP-1 health care costs have only begun to climb

First Opinion Jonathan Isaacsohn

Moving the conversation about obesity beyond the scale

The Readout LOUD Allison DeAngelis and Adam Feuerstein

STAT Plus: Listen: A new obesity startup, an acquisition gone wrong, & the future of Teladoc

Biotech Allison DeAngelis

STAT Plus: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs

Biotech Elaine Chen

STAT Plus: Eli Lilly’s Zepbound eases obstructive sleep apnea in trials

Health Andrew Joseph

European regulators find no evidence of link between new obesity medicines and suicidal thoughts

Pharma Elaine Chen

STAT Plus: Positive trial results set up obesity drug Wegovy for use against heart failure

First Opinion Patrick Skerrett

STAT readers on biotech and national security, liquid-only diets before colonoscopy, and the value of weight loss drugs

Biotech Elaine Chen

STAT Plus: Parkinson’s disease may be helped by GLP-1 drug, new study finds

First Opinion Dana P. Goldman and Alison Sexton Ward

Medicare coverage of weight loss drugs could save the U.S. billions of dollars

Health Elaine Chen

Ozempic-like drugs linked to low, but increased risk of post-endoscopy pneumonia, study finds

First Opinion Lisa Shah

Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it

Biotech Andrew Joseph

STAT Plus: Viking Therapeutics to move its oral obesity drug into Phase 2 study after early success

Pharma Andrew Joseph

STAT Plus: Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion

Health Elaine Chen

STAT Plus: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles

Biotech Damian Garde

STAT Plus: Regeneron’s plot to ‘cure’ allergies

Politics John Wilkerson

STAT Plus: Medicare expected to negotiate obesity drug prices soon, new analysis predicts

Insurance Rachel Cohrs Zhang

STAT Plus: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open

Biotech Adam Feuerstein

STAT Plus: First medicine developed to treat MASH expected to be approved soon

Letters to the editor Torie Bosch

STAT readers on new CDC Covid guidelines, weight loss drugs and mental health, and new psychiatric meds

Pharma Elaine Chen

STAT Plus: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: VC turmoil, GLP-1 competition, & the war on recovery

Biotech Allison DeAngelis

STAT Plus: Novo Nordisk’s obesity pill bests Wegovy in early trial

Pharma Andrew Joseph

STAT Plus: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows